552c7ae14ClaimYounger patients should receive priority when lifesaving treatment is scarceAgreeDisagree2
552c7ae14ClaimMedicare coverage of anti-obesity drugs would add about $35 billion to federal spending from 2026 to 2034AgreeDisagree
552c7ae14ClaimSemaglutide and tirzepatide are cost-effective for obesity at current net pricesAgreeDisagree
552c7ae14ClaimMost adults with obesity but without diabetes stop GLP-1 drugs within a yearAgreeDisagree
552c7ae14ClaimMedicare coverage of weight-loss drugs could save Medicare $175–245 billion over ten yearsAgreeDisagree
552c7ae14ClaimGovernments should license publicly funded drug patents to competitors when prices are unaffordableAgreeDisagree
552c7ae14ClaimPublic funding should prioritize access to established fertility treatment over enhancementAgreeDisagree
552c7ae14ClaimTying Medicare drug prices to international benchmarks will lower patient costs without reducing access to treatmentsAgreeDisagree
552c7ae14ClaimThe federal government should impose work requirements on Medicaid beneficiariesAgreeDisagree
552c7ae14ClaimCountries should presume consent to organ donation unless a person opts outAgreeDisagree
552c7ae14ClaimVoters are more likely to attribute fraud in Medicaid and Medicare to providers than to patientsAgreeDisagree
552c7ae14ClaimRising deductibles and upfront payment demands at doctor offices are driving voter anger on health costsAgreeDisagree
552c7ae14ClaimHealth care costs are the top health care issue for voters in the 2026 midterm electionsAgreeDisagree